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Post-partum haemorrhage has been highlighted as one of the most common 
causes of maternal deaths in third world countries. Oxytocin, a pharmaceutical 
neuropeptide, was identified as the drug of first choice to treat post-partum 
haemorrhage. It is currently available in the form of intravenous 
administration and requires cold-chain supply and storage condition as 
oxytocin degrades rapidly at 30 
o
C and above. Most third world countries 
experience tropical climate where temperature frequently hovers above 30 
o
C. 
Cold-chain supply and storage are often inadequate in these places. 
Additionally, in rural areas, most women give birth at home and intravenous 
injection requires skilled medical personnel to administer which are often not 
immediately available. In the present studies, intranasal delivery of oxytocin in 
aqueous micellar formulation is explored. Intranasal delivery of oxytocin 
eliminates the requirement of medical personnel to perform the injection. 
Furthermore, the neuroepithelium in the olfactory region of the nasal cavity 
facilitates the delivery of brain drug through the central nervous system, 
making intranasal delivery of oxytocin the preferred route of administration. 
Here, we developed surfactant micellar formulations using Tween 80, 
Cremophor RH40 and sucrose laurate for intranasal delivery of oxytocin in 
aqueous medium. Thermal stability of these formulations was evaluated and 
micellar formulation with sucrose laurate demonstrated enhanced stability of 
oxytocin at storage temperature of 40 
o
C while those with Tween 80 and 
Cremophor RH40 adversely affected the thermal stability of oxytocin. 
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Addition of a mucoadhesive, carboxylmethylcellulose, also negatively 
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Peptides are short chain amino acids with at least two amino acids linked by 
an amide or disulfide bond. The number of amino acids that makes up a 
peptide is arbitrarily defined to be less than 50 to distinguish peptide from 
protein (Kaspar et al., 2013). Peptides are attractive therapeutic drugs due to 
their high selectivity in binding with their in vivo targets at specific cell 
surface receptors, thus resulting in high efficacy with minimal side effects. 
Currently, more than 7000 naturally occurring peptides were identified and 
these often serve important biological functions in human physiology 
(Fosgerau et al., 2015). However, these natural peptides are usually not readily 
suitable for therapeutic purposes because of their poor chemical and physical 
stabilities as well as difficulties in crossing physiological barriers. Therefore, 
formulation strategies targeted at overcoming these intrinsic weaknesses of 
peptides are necessary before they can be approved pharmaceutics. 
 
Postpartum haemorrhage is defined as more than 500 ml or 1000 ml of blood 
loss for vaginal delivery and cesarean delivery respectively, within 24 hours 
following childbirth. In general, it is normal for bleeding to occur following a 
delivery due to open blood vessels after the separation of placenta from the 
uterus. The uterus typically continues to contract and these blood vessels will 
be closed off. However, some women may experience excessive blood loss 
and would require special treatment to stop the bleeding. Oxytocin, a 
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pharmaceutical peptide, is usually the first choice drug to be administered for 
the treatment of postpartum haemorrhage (Dyer et al., 2010). 
 
One of the Millennium Development Goals established by the United Nations 
is to reduce the maternal mortality ratio by 75%, between 1990 and 2015. 
Between 1990 and 2013, the maternal mortality ratio was decreased by 45% 
(United Nations). Clearly, progress was made but at a slower pace, and 
interventions are required to accelerate the reduction. Postpartum haemorrhage 
accounts for nearly 20% of maternal deaths worldwide. In addition, more than 
99% of maternal deaths due to postpartum haemorrhage happened in the 
developing countries (Say et al., 2014). 
 
Despite the success of oxytocin in treating postpartum haemorrhage thereby 
leading to a reduction in the maternal mortality rates in developed countries, 
postpartum haemorrhage is still the main cause of maternal death in many 
developing countries. This is largely due to the poor thermal stability of 
oxytocin in aqueous formulation, which requires a cold chain to maintain its 
drug integrity. Many developing countries experience tropical climate which is 
unfavorable to the stability of oxytocin and cold chain is usually lacking in 
these countries, especially in rural or remote areas. Additionally, current 
commercial oxytocin drug is administered intravenously by skilled medical 
personnel who may not be readily available in these remote places. It is 
therefore important to develop an oxytocin formulation that can be easily 
administered, and with improved heat stability in aqueous medium. The 
motivation of this work is to further bring down the maternal mortality rate, 
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especially in developing countries, by designing an oxytocin liquid 
formulation with enhanced thermal stability, suitable for intranasal 
administration, which would make cold chain unnecessary.  
 
 1.2 Objectives and Scope of Study 
 
The objective of the present work is to design and develop a heat-stable 
formulation for intranasal delivery of oxytocin. Nonionic surfactants, sucrose 
laurate, Cremophor RH40 and Tween 80, and the concentrations used were 
chosen based on availability of toxicological data for intranasal administration 
(Kürti et al., 2012). 
 
More specifically, the scope of this work encompasses the following: 
1. Studying the effect of salts on the critical micelle concentration of 
sucrose laurate, Cremophor RH40 and Tween 80. 
2. Studying the physical stability of oxytocin between 20 to 60 oC by 
monitoring the change in their droplet size and polydispersity index in 
various aqueous micellar formulations. 
3. Monitoring the thermal stability of oxytocin in various aqueous micellar 
formulations on storage temperature at 40 
o
C for three weeks by 
measuring the change in oxytocin concentration over time using HPLC. 
4. Investigating the effect of surfactant concentration on the thermal 
stability of oxytocin in aqueous micellar formulation. 
5. Investigating the effect of addition of mucoadhesives on the thermal 
stability of oxytocin in aqueous micellar formulation. 
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1.3 Organization of the Thesis 
 
Chapter 1 is the introduction of this thesis which provides an overview of this 
project. The objectives and scope of this work are outlined. Chapter 2 is the 
literature review section, providing an in-depth discussion on oxytocin, 
intranasal drug delivery and various strategies to formulate oxytocin for 
effective intranasal drug delivery. Chapter 3 describes the materials and 
experimental procedures employed in the study of oxytocin stability in the 
various formulations. Chapter 4 is a discussion on the results obtained from 
the experiments. Chapter 5 is the outlines the conclusions of the study. 
Chapter 6 highlights the limitations of this project and proposes future studies 
to better enhance the thermal stability of oxytocin in aqueous formulation for 








Oxytocin is a cyclic nonapeptide mammalian neurohypophyseal hormone, 
with molecular weight of 1,007.19 g/mol, produced by the hypothalamus and 
secreted by the posterior pituitary gland. It consists of a 20-membered cyclic 
link connected by a disulfide bridge between two cysteine amino acid groups. 
Its use is associated with uterine contraction and lactation simulation 
(Nachtmann et al., 1981; Chaibva et al., 2007). Oxytocin is used primarily in 
labor induction and augmentation, postpartum haemorrhage control and 
uterine hypotonoicity management in the third stage of labor (Chaibva et al., 
2007). 
 
2.1.1 Stability of oxytocin 
 
Oxytocin comprises a six-membered ring, Cys
1
 – Tyr2 – Ile3 – Gln4 – Asn5 – 
Cys
6
, and a three-membered tail, Pro
7





 by a disulfide bridge. Asn
5
 is responsible for oxytocin to serve its 









 are required for receptor binding (Walter et al., 1971). 
Degradation of oxytocin that resulted in structural changes could lead to loss 




Without special treatment, freeze-dried oxytocin acetate may remain stable for 
several years, with minimal loss of oxytocic activity, under refrigerated (2 – 
6
o
C) conditions (Nachtmann et al., 1981). However, the main problem with 
oxytocin stability occurs when it is incorporated in aqueous formulation at 
temperature 30 
o
C and above (Groot et al., 1994). Furthermore, the stability of 
aqueous oxytocin formulation is greatly dependent on the pH with highest 
stability at pH 4.5 (Hawe et al., 2009). The degradation products and 
mechanisms have been extensively studied and shall be discussed next. 
 
2.1.2 Degradation of oxytocin 
 
Peptide degradation in an aqueous solution may take place chemically and/or 
physically. Chemical degradation involves the modification of the peptide by 
covalent bond formation or covalent bond cleavage, resulting in a new 
chemical structure. For instance, peptide degradation by hydrolysis, oxidation, 
deamidation, disulfide exchange and β-elimination. In contrast, physical 
degradation occurs when the peptide undergoes higher order structural change 
such as dimerization.  
 
Oxytocin undergoes various degradation pathways, as shown in Figure 2.1, 
depending on target residues, pH and temperature. One of the most common 





 are susceptible to instantaneous 
deamidation to form aspartic acid, Asp, and glutamic acid, Glu residues 




 are mainly under acidic 
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conditions via direct acid catalyzed hydrolysis. Under neutral or alkaline 
conditions, deamidation occurs by the formation of cyclic imide intermediates, 
though the deamidation of Asn is more prevalent than that of Gln residues 
(Hawe et al., 2009). Additionally, the terminal Gly
9
 is also a likely target for 






Figure 2.1 Molecular structure of oxytocin with its ring and tail fragment 
ions formed upon MS/MS fragmentation (Avanti et al., 2012a). 
 
Peptides containing Cysteine (Cys) and Tyrosine (Tyr) are predisposed to 






 in oxytocin may 
occur in the presence of light and metal ions, and the process may be 
influenced by pH, temperature and buffer composition. Cys is especially 
sensitive to oxidative damage (Avanti et al., 2012a). 
 




 disulfide bridge may also be a site for potential 
chemical degradation. This can take place via β-elimination or disulfide 
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exchange reaction. Under alkaline condition or at elevated temperature, β-
elimination may occur, resulting in the destruction of the disulfide bridge to 
form free thiol groups. Under acidic condition, protonation of the disulfide 
bridge results in disulfide exchange reaction via the sulfenium cation. 
Disulfide exchange reactions could further lead to the formation of dimers or 
larger aggregates, and therefore destabilizing the formulation (Avanti et al., 
2012a). 
 
Physical degradation of oxytocin can be a result of dimerization, which in turn 
leads to aggregation. When more aggregates are brought together, 
precipitation is likely to occur. As discussed previously, dimerization can be 
brought about by disulfide exchange reaction. Additionally, dimers may also 
be formed due to light or metal induced oxidation. Also, heating, freezing or 
agitation may induced aggregation (Avanti et al., 2012a). 
 
2.1.3 Limitation and formulation challenges 
 
Several publications highlighted postpartum haemorrhage as one of the most 
common causes of maternal deaths in third world countries (Royston et al., 
1989; Van Dongen et al., 1991). Currently, oxytocin is available commercially 
under the trade name Syntocinon® as an aqueous solution for intravenous 
delivery. There are several problems associated with the use of Syntocinon in 
third world countries. First, Syntocinon has to be stored under refrigerated 
condition and cold-chain supply and storage are often inadequate in third 
world countries. Second, in rural areas where it is common for women to give 
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birth at home, medical provisions for intravenous delivery are often lacking 
which makes the use of Syntocinon even more challenging. Additionally, 
intravenous delivery of oxytocin is impractical in third world countries as it 
requires skilled medical personnel who are often not easily or immediately 
accessible to for the administration of the injection.  
 
Pulmonary delivery of oxytocin was explored in which ultrafine (1 – 5 m) 
oxytocin powder was formulated by spray-drying and aerosolized oxytocin 
has demonstrated potential for the design of a safe and inexpensive 
formulation for effective treatment of postpartum haemorrhage in resource-
poor settings (Prankerd et al., 2013). However, pulmonary delivery systems 
often encounter challenges with poor deposition of the drug as it has to 
overcome an efficient aerodynamic filter in the lung as well as to prevent 
deposited drugs from clearing back up the throat by the mucous lining in the 
pulmonary airway. Additionally, the stability of dry oxytocin is more sensitive 
to humidity than temperature (Groot et al., 1994). A lot of developing 
countries experience high humidity, suggesting the need for extra measures to 
ensure that the solid formulation is always kept away from moisture.  
 
Therefore, in this work, intranasal delivery of oxytocin is proposed as an 
alternative delivery route of administration. Furthermore, since powder sprays 
are more likely to trigger nasal mucosa irritation than solution or suspension 





2.2 Intranasal drug delivery of oxytocin 
 
Intranasal drug delivery has been used for treating and relieving a variety of 
nasal conditions and disorders for a long time. It has increasingly been 
recognized as a useful and reliable alternative to oral or parenteral systemic 
drug delivery. One of the advantages of intranasal drug delivery is that the 
drug can evade the blood-brain barrier, allowing more direct interaction of the 
drug with the central nervous system. This makes intranasal delivery of 
oxytocin, a neuropeptide, an attractive route of administration. Additionally, 
intranasal delivery circumvents the gastrointestinal and hepatic presystemic 
metabolism, thereby enhancing the bioavailability of oxytocin. 
 
2.2.1 Nasal cavity 
 
Breathing and smelling seems to be the more apparent functions of the nasal 
cavity. More importantly, the nasal cavity is part of the respiratory system 
whereby inhaled air is pretreated for proper respiratory function. Inhaled air is 
heated or cooled, filtered and humidified in the nasal cavity before entering 
the lungs. Mucus and hairs lining the nasal cavity help to trap inhaled particles 
and pathogens, preventing them from entering the lungs (Mygind et al., 1998). 
 
A human nasal cavity has an estimated total volume and total surface area of 
15 ml and 150 cm
2
 (Mygind et al., 1998). The nasal cavity is divided into four 
main areas which include the nasal vestibule, atrium, respiratory region and 




Figure 2.2 Anatomy and histology of human nasal cavity (Pires et al., 
2009). 
 
Just inside the nostrils is the nasal vestibule, which consists of nasal hairs, that 
filters inhaled particles from the air that we breathe in. This region is lined 
with stratified squamous and keratinized epithelium, mainly to provide 
protection against toxic environmental substances. It is likely that the 
protection against toxic substances is due to poor permeability in the nasal 
vestibule, which suggests that drug absorption in the nasal vestibule is low 
(Illum, L., 2003; Probst et al., 2011; Kimbell et al., 1997).  
 
Inhaled air crosses the nasal vestibule into the atrium, which comprises the 
stratified squamous in the anterior portion and the pseudostratified columnar 
cells with microvilli, before entering the respiratory region.  The atrium does 
not offer much absorption activity.  
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Inhaled air from the atrium subsequently enters the respiratory region which is 
the largest section of the nasal cavity, with a total surface area of 
approximately 130 cm
2
. The large surface area can be attributed to the 
presences of mucosa-covered folds, which are the superior, middle and 
inferior turbinates, projected from the lateral wall. Pseudostraified columnar 
epithelial cells with microvilli line the wall of the nasal cavity also help 
enhance the respiratory surface area. The large surface area in the respiratory 
region is where the humidification and temperature regulation of inhaled air is 
carried out in the nasal cavity. Secretory glands and goblet cells present in the 
epithelium in the respiratory region are responsible for production of nasal 
mucous which thinly coat the nasal epithelium. The nasal mucous is 
approximately 95% water, 2.5-3% mucin and 2% electrolytes, proteins, lipids, 
enzymes, antibodies, sloughed epithelial cells and bacterial products (Dondeti 
et al., 1996; Verdugo, 1990; Lethem, 1993). The nasal mucous is important 
for several reasons. First, it is required for the humidification and temperature 
adjustment of inhaled air. Next, the adhesive behavior of the mucous helps to 
trap inhaled particulates and pathogens. The nasal mucociliary clearance then 
function to transport these trapped particles to the mouth towards the 
nasopharynx, to be removed by swallowing or coughing (Kim, 2008). 
Pathogen binds with mucin, found in the nasal mucous produced by epithelial 
tissue, to form part of the human immune system. Additionally, mucin can 
bind with large molecules, such as peptide drugs, for drug delivery 
(Constantino et al., 2007). Furthermore, the provision of high surface area in 
the nasal respiratory region, together with the high vascularization beneath the 
epithelium with good permeability, is important for drug delivery.  
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The olfactory region is the only region that is part of the central nervous 
system that provides opportunity for direct contact to the external environment. 
It is located on the roof of the nasal cavity near the septum. Its epithelial 
structure is similar to that in the respiratory region except that a special 
olfactory receptor cells is also present. These receptor cells binds to odor 
molecules and are important for the detection of smell. 
 
2.2.2 Advantages of intranasal drug delivery 
 
Intranasal delivery of oxytocin offer several advantages compared to other 
route of delivery. In comparison with parenteral delivery, the most apparent 
advantages would be comfort and ease of administration. Intranasal delivery is 
non-intrusive and can be self-administered easily, eliminating the need of 
skilled medical personnel. Next, deposition of oxytocin is more effective in 
the respiratory and olfactory region of the nasal cavity than that in the lungs. 
This may be due to the relative difference in distance the drug has to travel to 
the target sites as well as the resistance present in the pulmonary airway. In 
addition, Oral delivery is irrelevant as peptides generally have poor stability in 
the gastrointestinal environment, poor intestinal absorption and extensive 
hepatic first-pass elimination (Illum, L., 2003). Hence, the gastrointestinal 
region can be avoided for intrasanal delivery. Furthermore, the activity of 
oxytocin targets the brain. The neuroepithelium in the olfactory region 
facilitates the delivery of brain drug through the central nervous system, 




2.2.3 Limitations of intranasal drug delivery 
 
Inside the nasal cavity, the central nervous system is separated from the 
outside environment by the mucous layer and the epithelial membrane. The 
efficacy of intranasal drug delivery may be influenced by a number of factors 
and these can be divided into three categories, namely the nasal physiology, 
the drug physicochemical properties and the drug formulation. 
 
2.2.3.1 Nasal physiology 
 
For nasal physiology, blood flow in the nasal mucosa, mucociliary clearance, 
enzyme degradation in nasal tissue and the presence of drug resistance 
transporter in the nasal tissue. First, absorption of drug is influenced by the 
blood flow in the nasal mucosa. The main mechanism for drug absorption is 
diffusion. Drugs may exhibit vasodilatation or vasoconstriction effect 
depending on vascular body which affects the flow of blood which in turn 
influences the drug diffusion. However, in a recent study, Ludwig et. al. 
suggested that intranasal administration of oxytocin in rats did not 
substantially affect the heart rate and arterial pressure, implying negligible 
vasodilatation or vasoconstriction (Ludwig et al., 2014).  
 
Next, the complexity of the mucociliary clearance can affect nasal drug 
absorption in several ways. For instance, abnormal transport rate of mucus and 
its residence time can impair the mucociliary clearance (Marttin et al., 1998). 
A slower mucociliary clearance results in longer residence time of the drug in 
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the nasal mucosa thereby increasing drug permeation. On the contrary, a faster 
mucociliary clearance leads to shorter residence time, implying premature 
discharge of administered drugs from nasal cavity and resulting in poor 
absorption. Additionally, site of drug deposition affects drug absorption as 
well, which is highly affected by dosage form. For nasal spray, drugs are 
deposited more anteriorly compared to drugs administered by nasal drops 
(Illum, L., 2003). Mucociliary clearance is more active in the posterior part of 
the nasal cavity than the anterior part (Marttin et al., 1998). Hence, nasal drops 
have faster mucociliary clearance than nasal spray. Also, polar drugs 
solubilize easily in the mucus but permeate slowly across the membrane. 
Therefore, polar drugs suffer from poor absorption due to high mucociliary 
clearance.  Furthermore, drug absorption can be influenced by external factors 
that affect the mucociliary clearance which includes temperature, presence of 
sulphur dioxide, cigarette smoking, drug formulation and variability in 
mucociliary clearance between different people. 
 
Enzymatic degradation may also have a negative impact on nasal drug 
absorption. Numerous metabolic enzymes are found in the nasal cavity and 
these may affect the pharmacokinetic and pharmacodynamics profile of the 
administered drug. More specifically, proteolytic enzymes found in the nasal 
cavity can be detrimental to the absorption of peptide drugs, such as oxytocin. 
However, nasal first-pass metabolism is normally less destructive than hepatic 
or intestinal metabolism. Nevertheless, it cannot be ignored and requires 




Another aspect of nasal physiology that influences drug delivery is the 
presence of transporter systems in nasal tissue. Several studies (Graff et al., 
2005; Westin et al., 2005; Kandimalla et al., 2005) have identified drug 
resistance transporter molecules present in the human nasal respiratory and 
olfactory mucosa, which hinder the absorption of drug across the nasal 
membrane into the central nervous system. 
 
2.2.3.2 Drug physicochemical properties 
 
The physicochemical properties of the drug may affect nasal drug absorption. 
First, hydrophobicity and molecular weight of the drug. Hydrophobic drugs 
1kDa or smaller can be readily absorbed across the nasal membrane. Drugs 
with molecules larger than 1 kDa may exhibit reduced absorption. In contrast, 
hydrophilic drugs show poor absorption and are highly dependent on their 
molecular weight. This is due to the lipophilic nature of the nasal membrane 
which has greater compatibility with increased lipophilicity. However, drugs 
that are too hydrophobic are unable to dissolve in the mucus readily and will 
be removed by mucociliary clearance, thereby reducing the permeation 
through nasal mucosa. For hydrophilic drugs, such as oxytocin, absorption 
through the nasal membrane is further influenced by their ionization strength 
and the pH of the nasal mucosa which is between 5.0 and 6.5. It was found 
that largest permeation through the nasal mucosa is for non-ionized species 
and decreased with increased degree of ionization (Corbo et al., 1989; Hirai et 




Additionally, nasal drug absorption is also affected by the intrinsic biological, 
chemical and physical drug stability. This is especially relevant to oxytocin 
with poor thermal stability in the aqueous environment as previously discussed.  
 
Drug absorption is influenced by its water solubility as it is required to 
dissolve in the fluid of the nasal cavity for contact with the nasal mucosa and 
posterior absorption (Zaki et al., 2006). Furthermore, the volume of drug 
solution administered is constrained by the small size of the nasal cavity. 
Hence, the drug solubility in the delivery medium has to be sufficiently high to 
be effective.  
 
2.2.3.3 Drug formulation 
 
Drug formulation is likely to influence the nasal drug absorption as well. First, 
viscosity of the drug affects the residence time of the drug in the nasal cavity. 
In general, formulation with high viscosity may increase drug absorption due 
to the increased in contact time between the drug and the nasal mucosa. 
However, increased in formulation viscosity does not always imply an 
increased in drug absorption. Zaki and coworkers reported that enhanced 
viscosity of formulation with metoclopramide hydrochloride in the nasal 
cavity resulted in the reduction in drug absorption (Zaki et al., 2006). This is 
likely the result of slow diffusion which leads to poorer drug absorption. 
 
The pH of drug formulation may also have an impact on nasal drug absorption. 
It is essential to select a formulation pH that would minimize nasal mucosa 
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irritation, at the same time maintaining drug stability. The pH of the human 
nasal mucosa is between 5 and 6.5 (Washington et al., 2000). Potential nasal 
irritation can be avoided by formulating the drug delivery system between pH 
4.5 and 6.5. Additionally, at this pH condition bacteria growth may be 
impeded. (Arora et al., 2002). 
 
Furthermore, the pharmaceutical dosage forms and the types of 
pharmaceutical excipients used may also affect the nasal drug absorption. 
Nasal drops are often the most convenient form but delivering the required 
dose accurate is a challenge. Solution or suspension sprays are often preferred 
over nasal drops. Pharmaceutical excipients present in nasal formulation, such 
as buffer components, gelling agents, and solubilizers, may also alter the drug 
absorption profile. 
 
2.2.4 Methods to improve nasal drug absorption 
 
As previously discussed, oxytocin is a relatively hydrophilic peptide and it is 
likely that absorption through the lipophilic membrane of the nasal cavity is 
poor. Furthermore, the mucociliary clearance adversely affects the absorption 
of polar drug in the nasal cavity. Hence, intranasal formulation design needs to 
take into consideration these two factors to ensure sufficient bioavailability. 
 
There are many ways to improve the absorption of hydrophilic drug in the 
nasal cavity. For instance, absorption enhancer may be added to assist the 
crossing of hydrophilic drugs through the nasal epithelium. It is likely that the 
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addition of absorption enhancer induces reversible structural change to the 
epithelial barrier, thereby increasing its compatibility with hydrophilic drug 
leading to better absorption. Absorption enhancer for intranasal delivery may 
be surfactants, bile salts, fatty acids or polymeric enhancers, such as gelatin, 
cyclodextrins, chitosan and poly-L-arginine (Charlton et al., 2007; Wang et al., 
2006; Hersey et al., 1987; Mishima et al., 1987; Baglioni et al., 1990; Illum et 
al., 1994; Ekelund et al., 2005). Depending on the type of absorption enhancer 
used, the epithelial cells may be affected in different ways. In general, the 
phospholipidic layer may be modified, the membrane fluidity may be 
increased or the tight junctions between epithelial cells may be opened, 
resulting in increased in paracellular transport (Karasulu et al., 2008). 
Selection of absorption enhancers need to take into consideration their 
intranasal toxicity for safe administration of the formulation. 
 
Additionally, the effect of mucociliary clearance on the absorption of polar 
drug may be minimized by the addition of mucoadhesives. Mucoadhesives are 
synthetic or natural polymeric compound, such as chitosan, alginate, cellulose 
and their derivates, added to formulation to interact with mucin in the nasal 
mucosa. Upon contact with the mucus layer, the formulation becomes wet and 
swells. The mucoadhesives then penetrate into the mucus, thereby creating a 
localization of the formulation in the nasal cavity, which lead to an increased 





2.3 Formulation strategies for intranasal delivery of oxytocin in 
aqueous medium 
 
Developing a stable oxytocin formulation in aqueous medium at elevated 
temperature is challenging due to its poor thermal stability. On top of that, the 
hydrophilic nature of oxytocin may adversely impact its bioavaibility in the 
nasal cavity. Therefore, it is important that these are taken in consideration in 
formulation design. Formulation components with acceptable toxicity 
tolerance have to be thoughtfully selected for safe administration in the human 
nasal cavity. 
 
2.3.1 Oxytocin stabilization 
 
The degradation kinetics of oxytocin in aqueous environment were studied by 
Hawe and coworkers and they discovered that the degradation profile of 
oxytocin is greatly dependent on the pH of the formulation. They concluded 
that oxytocin is most stable in formulation at pH 4.5 (Hawe et al., 2009). 
Therefore, designing oxytocin formulation with pH 4.5, thermal degradation 
by oxidation and -elimination at Cys1 and Cys6 is more prevalent than the 
other degradation processes at other sites.  
In another study by Avanti and coworkers, they found out that use of citrate 
buffer at pH 4.5 greatly enhances the thermal stability of oxytocin in aqueous 
formulation for parenteral delivery. Additionally, the presence of divalent 






, significantly impact the stability of 
oxytocin favorably. They suggested that a synergistic effect exists when citrate 
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buffer and the divalent salts are added into the aqueous oxytocin formulation 
(Avanti et al., 2011). 
 
In a separate study by Avanti and coworkers, the mechanism of stabilizing 
oxytocin in aqueous formulation with a citrate buffer and divalent metal ions 





were suppressed when a citrate buffer was used in the presence of divalent 
metal ions. A complex is likely formed in the ring structure of oxytocin 
thereby suppressing intermolecular reactions. There were no observable 






 were used. Hence, they concluded 
that divalency is essential for stabilization of oxytocin in aqueous formulation 
(Avanti et al., 2012b). 
 
2.3.2 Formulation components 
 
Components for design of oxytocin formulation need be safe for intranasal 
administration in human beings. In addition, the components need to be used 
at the appropriate concentrations while maintaining its desired function.  
 
Non-ionic surfactants are in general less toxic to biological membranes than 
ionic surfactants (Arechabala et al., 1999). Both Cremophor RH40 and Tween 
80 are non-ionic surfactants used to increase cell membrane fluidity or 
augmenting paracellular absorption (MacDonald et al., 2010). Sucrose esters 
are non-ionic surfactants that are biodegradable and have shown to be non-
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toxic and non-irritant to the skin. There is evidence that show the use of 
sucrose esters as permeation enhancers through the skin (Csoka et al., 2007).  
 
In 2012, a study by Kürti and coworkers evaluated the non-toxic doses of 
sucrose laurate, Cremophor RH40 and Tween 80 to the human nasal epithelial 
cells. They have found that sucrose laurate, Cremophor RH40 and Tween 80 
can safely be administered intranasally at 0.1 mg/ml, 5 mg/ml and 1 mg/ml. 
Furthermore, they also concluded that these non-ionic surfactants can 
potentially be used as permeation enhancers in nasal formulations (Kürti et al., 
2012). 
 
In addition to absorption enhancers, mucoadhesives may also be added into 
aqueous oxytocin formulation to increase its bioavailability. Ugwoke and 
coworkers have proven that Carbopol 971® and carboxylmethylcellulose can 
be used to increase the residence time of the formulation in the nasal cavity 
(Ugwoke et al., 2000a). Toxicological studies on Carbopol 971® and 
carboxylmethylcellulose to determine if they can be used in nasal formulations 
were carried out. In an in vivo intranasal administration of Carbopol 971® in 
rabbits, it was found that Carbopol 971® resulted in severe inflammation in 
the nasal mucosa in rabbits (Ugwoke et al., 2000b). On the other hand, 0.25% 
(w/v) of carboxylmethylcellulose was well tolerated, showing no inhibitory 
effect on the ciliary beat frequency in the human nasal epithelial cell culture, 





Absorption enhancers and mucoadhesives are selected based on available 
toxicity data. Therefore, in this work, aqueous oxytocin formulations with 
absorption enhancers, sucrose laurate, Cremophor RH40 or Tween 80, and 
mucoadhesives, carboxylmethylcellulose, at their safe doses were developed 








Oxytocin acetate was purchased from Sinoway Industrial Co., Ltd. (Xiamen, 
China). Food grade sucrose laurate [L-1695, HLB = 16, average molecular 
weight = 560 g/mol] consisting of not less than 80% of mono-, di-, and tri-
esters was provided by Mitsubishi-Kagaku Foods Corporation (Tokyo, Japan). 
Sorbitan monooleate (Tween 80), Polyoxyl 40 hydrogenated castor oil 
(Cremophor® RH40), Carboxymethylcellulose sodium salt (low viscosity) 
and sodium citrate dehydrate were purchased from Sigma-Aldrich. Citric acid 
monohydrate and zinc chloride were obtained from Merck KGaA. Potassium 
dihydrogen phosphate was purchased from Alfa Aesar. Sodium hydroxide 
pellets was obtained from Schedelco Pte Ltd. Chemicals used for HPLC assay 
were HPLC grade supplied by J.T. Baker. All other chemicals were used as 
received without further purification. Ultra-pure water (Millipore-Q® 
Gradient A10™ ultra-pure water system, Millipore, France) was used 
throughout the study. 
 
3.2 Critical micelle concentration determination 
 
The critical micelle concentration (CMC) of sucrose monolaurate, Cremophor 
RH40 and Tween 80 in pure water were published as shown in Table 3.1. In 
this study, sucrose laurate containing a mixture mono-, di-, and tri-laurate was 
used. Deviation of the CMC from published value is possible. The CMC of the 
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sucrose laurate mixture was evaluated by surface tensiometry in pure water at 
25 
o
C. Sucrose laurate in concentration ranging from 0.0005 mg/ml to 10 
mg/ml in ultra-pure water were prepared and their surface tensions (, mN/m) 
were measured by Attension Sigma 700 Force Tensiometer using a standard 
Du Noüy ring [R(ring) = 9.58 mm, R(wire) = 0.185mm]. The surface tension 
was measured at fixed interval for ten minutes until the values agreed within 
0.1 mN/m of each other for three consecutive readings. The final surface 
tension was recorded. All samples were prepared in triplicate and the mean 
values were taken. 
 
Table 3.1 Critical micelle concentration of sucrose monolaurate, 




A plot of surface tension vs logarithm of concentration was obtained for the 
determination of CMC values. At very low surfactant concentration, the 
surface tension decreased with increased in surfactant concentration. The 
CMC therefore corresponds to the concentration at which the surface tension 
does not continue to change significantly with further increase in surfactant 
concentration.  
 
Surfactant CMC [mg/ml] Reference 
Sucrose monolaurate 0.18 Youan et al., 2003 
Cremophor RH40 0.1 Matsaridou et al., 2012 
Tween 80 0.017 Kerwin, 2007 
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Additionally, the formulations were prepared with citrate buffer containing 
Zn
2+
 metal ions as the aqueous phase. As the CMC of the surfactants can be 
affected by the addition of buffer and divalent salts, the operative CMC of the 
respective surfactants were also determined in the aqueous phase in the same 
manner. Solutions of sucrose laurate, Cremophor RH40 and Tween 80 were 
prepared in the aqueous citrate buffer with Zn
2+
 metal ions at different 
concentrations, ranging from 0.0001 mg/ml to 10 mg/ml and their CMC 
values were estimated based on surface tensions measurement. 
  
3.3 Formulation development and stability study 
 
Sucrose laurate, Cremophor RH40 and Tween 80 were selected for the 
development formulation of oxytocin in 10 mM citrate buffer pH 4.5 
consisting of 2 mM Zn
2+
 divalent metal ions. The formulation development 
process is outlined in Figure 3.1. 10 mM citrate buffer at pH 4.5 with of 2 
mM Zn
2+
 divalent metal ions was prepared as aqueous phase and used as the 
control experiment. Sucrose laurate, Cremophor RH40 and Tween 80 were 
solubilized in the aqueous phase at 0.1 mg/ml each. 0.1 mg/ml of oxytocin was 
then solubilized in each of the micellar formulations. The formulations were 
stored at 40
o
C for three months and the recovery of oxytocin was analyzed 
using High-Performance Liquid Chromatography (HPLC) to compare the 
thermal stability of oxytocin in the different micellar formulations against the 
control. Subsequently, the concentrations of surfactants used were increased 
up to their maximum tolerable limit for intranasal delivery, i.e. 5 mg/ml and 1 
mg/ml for Cremophor RH40 and Tween 80 respectively, and the thermal 
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stability of oxytocin in these formulations were monitored. For sucrose laurate, 
0.1 mg/ml was already the maximum non-toxic dose and was therefore 
excluded for this part of the study. Lastly, mucoadhesives, 
carboxymethylcellulose was added to the formulations that demonstrated 
enhanced thermal stability of oxytocin in aqueous formulations and its effect 




















Figure 3.1 Formulation design procedure 
0.1 mg/ml oxytocin 
0.1 mg/ml Cremophor 
RH40 
+Maximum safe limit for 
intranasal delivery 
*Control 
Citrate buffer pH 4.5 with 2 mM 
Zn2+ divalent metal ions* 
0.1 mg/ml sucrose 
laurate L-1695+ 
0.1 mg/ml Tween 80 
Effects of higher surfactant concentration on aqueous 
oxytocin thermal stability 
5 mg/ml Cremophor 
RH40 
1 mg/ml Tween 80 
Effects of mucoadhesive (carboxymethylcellulose) addition on aqueous oxytocin 
thermal stability 
Addition of 2.5 mg/ml carboxymethylcellulose+ to successful micellar formulation 





3.4 Micellar droplet size and polydispersity index measurement by 
Dynamic Light Scattering 
 
The micellar droplet size and polydispersity index of 0.1 mg/ml of sucrose 
laurate, Cremophor RH40 and Tween 80 formulations with 0.1 mg/ml 
oxytocin were measured, for the temperature range between 20 and 60 
o
C, by 
the Dynamic Light Scattering (DLS) technique. The Malvern Zetasizer Nano 
ZS (Malvern Instrument Ltd., UK) was used, which consists of a 4mW He-Ne 
laser (λ = 633 nm) with detection angle 173°. The change in intensity pattern 
of light scattered by the droplets in the micellar formulation is tracked and this 
is use for the determination of diffusion coefficient. The Stokes-Einstein 
equation (Equation 3.1) is utilized to calculate the hydrodynamic diameter, dH, 
of the droplet based on the diffusion coefficient, assuming the droplets are 




  (𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑. 𝟏) 
where kB is the Boltzmann constant; T is absolute temperature;  is viscosity 
and D is diffusion coefficient. Samples were measured undiluted. Three 
independent experiments (N = 3) were performed and each experiment was 







3.5 Quantitative analysis by High-Performance Liquid 
Chromatography 
 
The concentration of oxytocin in the aqueous formulations were quantified 
using an Agilent 1100 series HPLC system which consists of a standard 
quaternary pump, a variable wavelength detector (VWD), an auto-sampler and 
a vacuum degasser (Model G1311A) controlled by Chemstation software. 
Chromatographic column, ZORBAX Eclipse Plus C18, 4.6 × 250 mm, 5 
micron packing size, Agilent Technologies, was used for separation of 
oxytocin from the rest of the excipients in the formulation. The mobile phase 
is a mixture of 80 vol. % 80 mM Phosphate Buffer pH 5 and 20 vol. % 
acetonitrile. The elution flow rate was maintained at 1 ml/min with a sample 
injection volume of 20 l. The UV detection wavelength was fixed at 220 nm. 
The analysis was carried out at 25 
o
C. The retention time of oxytocin was 
approximately 7 minutes.  
 
The initial amounts of oxytocin were measured in each of the formulations 
using HPLC in terms of peak absorbance area. Oxytocin concentrations in the 
formulations were monitored over three months. The recovery of oxytocin was 
calculated as percentage of the initial peak absorbance area. For each 
formulation, three same samples were prepared for statistical evaluation of 





3.6 Statistical analysis 
 
One-way analysis of variance (ANOVA) was used to analyze the results 
performed in Section 3.5. The results were deemed statistically different when 




CHAPTER 4 RESULTS AND DISCUSSION 
 
4.1 Critical micelle concentration determination of micellar 
formulation 
 
Based on surface tension measurement as shown in Figure 4.1, the CMC of 
sucrose laurate in pure water at 25 
o
C is estimated at 0.205 mg/ml. This value 
is similar to published data which was displayed in Table 3.1. Even though 
sucrose laurate is a mixture of sucrose mono-, di- and tri-laurate, the measured 
CMC is approximately the same as that of pure sucrose monolaurate in water. 
 
 
Figure 4.1 Surface tension as a function of sucrose laurate L-1695 
concentration in pure water for determination of critical micelle concentration. 
 
For nonionic surfactant, the CMC value may be influenced by the addition of 
salt which can either increase or decrease the CMC depending on the type of 
surfactant and salt used (Kronberg et al., 2014). Furthermore, sucrose laurate 


















Surfactant concentration [mg/ml] 
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therefore important to evaluate the operative CMC value of sucrose laurate in 
the aqueous citrate buffer solution with Zn
2+
 ions to confirm if micellization 
takes place.  
 
The surface tension measurement of sucrose laurate L-1695, Cremophor RH40 
and Tween 80 in citrate buffer pH 4.5 with Zn
2+
 ions are plotted as shown in 
Figure 4.2-4.4. The CMC at 25 
o
C were tabulated in Table 4.1. It can be 
observed that the presence of inorganic salt resulted in an order of magnitude 
reduction in CMC values for sucrose laurate and Cremophor RH40 solutions 
but an increased in CMC value for Tween 80. In general, a change in CMC is 
largely related to the salting effect by electrolyte addition (Carale et al., 1994; 
Ray et al., 1971; Ruiz, C.C., 2008). CMC decreases due to salting out effect 
while CMC increase because of salting in effect. Salts are either ‘water-
structure-making’ or ‘water-structure-breaking’ in nature (Nishikido et al., 
1977; Ruiz, C.C., 2008). The presence of salts in the aqueous environment can 
either promote hydration or dehydration of the surfactant molecules.  The 
salting out effect occurs when the addition of water-structure-making salts 
resulted in attraction of water molecules around the ions, reducing the water 
molecules in the bulk, causing the dehydration of the surfactant molecules. 
The solubility of the surfactant is decreases, resulting in greater driving force 
for micellization, therefore reducing the CMC. On the other hand, water-
structure-breaking salts increase the amount of water molecules in the bulk 
solutions, allowing better hydration of the surfactant molecules which is the 
salting in effect. Solubility of the surfactant is increased and CMC is increased. 
In addition, Zn
2+
 ions can form complex with ether linkages in 
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polyoxyethylene, which imparts a positive charge to the polar head group 
(Schott, 1973; Schott et al., 1976).  The nonionic surfactant becomes cationic 
and the resultant electrostatic repulsion between cationic molecules raises the 
CMC, implying salting in.  
 
Figure 4.2 Surface tension as a function of sucrose laurate concentration in 
citrate buffer pH 4.5 with 2 mM Zn
2+
 divalent metal ions for determination of 
critical micelle concentration. 
 
 
Figure 4.3 Surface tension as a function of Cremophor RH40 
concentration in citrate buffer pH 4.5 with 2 mM Zn
2+
 divalent metal ions for 









































Figure 4.4 Surface tension as a function of Tween 80 concentration in 
citrate buffer pH 4.5 with 2 mM Zn
2+
 divalent metal ions for determination of 
critical micelle concentration. 
 
 
Table 4.1 Critical micelle concentration of sucrose laurate L-1695, 
Cremophor RH40 and Tween 80 in citrate buffer pH 4.5 with 2 mM Zn
2+
 




CMC in pure water 
[mg/ml] 




Sucrose laurate L-1695 0.205 0.046 
Cremophor RH40 0.1 0.022 
Tween 80 0.017 0.042 
 
 
In this case, sucrose laurate does not contain polyoxyethylene group and hence, 
salting out by dehydration of surfactant molecules is probable. For Cremophor 
RH40 micellar formulation, complex formation with Zn
2+
 may be impeded 
due to steric interference. Dehydration effect of the surfactant molecules is 



















Surfactant concentration [mg/ml] 
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salting out of the surfactant leads to reduction in CMC. For Tween 80, it may 
be possible that salting in effect due to complex formation with Zn
2+
 is more 
dominant than salting out effect due to dehydration of surfactant molecules. 
Therefore, CMC is increased. 
 
For all the formulations prepared for this study, the surfactants are used at 
concentration above CMC. Hence, it is reasonable to regard them as micellar 
formulations. More specifically, these formulations are normal micellar 
systems since the disperse phase is the aqueous environment. 
 
4.2 Physical stability of oxytocin in micellar formulation 
 
The change in the hydrodynamic droplet diameter of the micelle in the 
formulation was measured by DLS at temperature ranging from 20 to 60 
o
C. 
Figures 4.5-4.7 show the results obtained from DLS measurement. Based on 
Figures 4.5(i), there is a general increased in the hydrodynamic droplet 
diameter with increased in temperature, demonstrating the temperature 
dependence of the micellar formulations of sucrose laurate. The droplet size 
for sucrose laurate micellar formulation increased from 259.4 to 482.7 nm 
when the temperature is increased from 20 to 60 
o
C. On the contrary, with 
reference to Figure 4.6(i) and 4.7(i), the micellar droplet sizes for the 
Cremophor RH40 and Tween 80 formulations were not significantly affected 
by temperature. The mean hydrodynamic diameter fluctuates between 14.18 
and 15.19 nm for Cremophor RH40 and 10.92 and 24.47 nm, implying that 
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micellar formulation of Cremophor RH40 and Tween 80 has better thermal 
stability up to 60 
o
C as compared to that of sucrose laurate.  
 
 
Figure 4.5 Hydrodynamic diameter (dH) and polydispersity index of droplets 
in (i) 0.1 mg/ml sucrose laurate (ii) 0.1 mg/ml sucrose laurate with 0.1 mg/ml 




Figure 4.6 Hydrodynamic diameter (dH) and polydispersity index of droplets 
in (i) 0.1 mg/ml Cremophor RH40 (ii) 0.1 mg/ml Cremophor RH40 with 0.1 













































































































































































Figure 4.7 Hydrodynamic diameter (dH) and polydispersity index of droplets 
in (i) 0.1 mg/ml Tween 80 (ii) 0.1 mg/ml Tween 80 with 0.1 mg/ml oxytocin 
formulations. (n = 5) 
 
Large micelles tend to be very polydisperse (Kronberg et al., 2014). Sucrose 
laurate micellar droplets are larger than those of Cremophor RH40 and Tween 
80. The mean polydispersity index of the Cremophor RH40 and Tween 80 
micellar formulations are both less than 0.5 between 20 and 60 
o
C while that 
for the sucrose laurate micellar formulation fluctuates between 0.465 and 
0.579 in the same temperature range. This shows that the micellar droplet of 
the Cremophor RH40 and Tween 80 formulations are relatively more 
homogeneous than that of the sucrose laurate formulation. For the Cremophor 
RH40 formulation it is the most homogeneous, with polydispersity index of 
less than 0.1 at the given temperature range depicting monodispersed sample. 
However, for Tween 80 and sucrose laurate formulations, PDI are above 0.2, 




























































































Figure 4.5(ii), 4.6(ii) and 4.7(ii) show the effect of temperature on the droplet 
size and polydispersity index of the micellar formulations with the addition of 
oxytocin. It can be seen that the micellar droplet size for sucrose laurate 
formulation is reduced after oxytocin is added. In addition, a slight increase in 
the mean polydispersity index of the sample across the temperature range was 
detected. Conversely, the droplet size and polydispersity index for Cremophor 
RH40 micellar solution did not change significantly with the introduction of 
oxytocin into the formulation. For Tween 80 formulation, oxytocin addition 
resulted in a slight increase in the average droplet size of the micellar 
formulation, ranging between 15.13 and 33.54 nm in the temperature 20 to 60 
o
C. Additionally, the formulation is slightly more polydispersed with 




It is evident that oxytocin showed negligible interaction with the base 
Cremophor RH40 micellar formulation since the hydrodynamic diameter and 
polydispersity index is relatively unaffected by the addition of oxytocin. 
However, interactions of oxytocin with sucrose laurate and Tween 80 micelles 
are clearly present, resulting in changes in the droplet sizes and polydispersity 
indices.  
 
For sucrose laurate micelles, the reduction in droplet size by the addition of 
oxytocin is possibly due to oxytocin behaving like a co-surfactant. A co-
surfactant is amphiphilic consisting of terminal hydroxyl group. It interacts 
with the micelle at the interface which then affects the micellar curvature and 
interfacial energy (Alany et al., 2000). This results in the increase in 
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interfacial fluidity due to the penetration of co-surfactant into the surfactant 
monolayer and creates void spaces among surfactant molecules in the 
monolayer (Constantinides et al., 1997). The bending rigidity of the 
monolayer is then reduced (Kozlov et al., 1992) which favors the formation of 
smaller micelles (El Maghrab, 2008). Oxytocin is made up of amino acids that 
are both polar and nonpolar as simplified in Figure 4.8. The three-membered 
tail, Pro
7
 – Leu8 – Gly9, are all nonpolar amino acids while the six-membered 
ring, Cys
1
 – Tyr2 – Ile3 – Gln4 – Asn5 – Cys6, consists of all polar amino acids 
except Ile
3
 which is nonpolar. Based the structural analysis, it seems that 
oxytocin exhibits amphiphilic behavior. In addition, the tyrosine amino acid 
has a terminal hydroxyl group.  Therefore, it can be postulated that addition of 
oxytocin reduces the droplet size of the sucrose laurate micelle due to co-
surfactant behavior of oxytocin. 
 
 
Figure 4.8 Simplified chemical structure of oxytocin showing potential 












For Tween 80, it may be possible that the oxytocin molecules interact with the 
interface of the Tween 80 micelles, therefore resulting in slightly larger 
droplet size. In general, there are several possible site where micellar 
solubilization can take place in a normal micellar system depending on the 
hydrophilicity/lipophilicity of the solubilizate. With reference to Figure 4.9 
(Tadros, 2005), lipophilic solubilisate is incorporated in the non-polar core 
while hydrophilic solubilisate can either be located within the core, short or 
deep penetration, or be adsorbed on the micellar surface. In addition, for 
surfactants with polyoxyethylene chain in the polar head group, hydrophilic 
drug can also be trapped within the polyoxyethylene chains of the micelle. The 
slight increase in the droplet size of Tween 80 micelles by the addition of 
oxytocin is probably due to the solubilization of oxytocin by the Tween 80 
micelles at the surface or shallow penetration into the polar head group.  
 
 
Figure 4.9 Site of incorporation of solubilisate: (a) in the hydrocarbon core; 
(b) deep penetration; (c) short penetration; (d) adsorption; (e) in the 









4.3 Thermal stability of oxytocin in micellar formulation 
 
In this section, the thermal stability of oxytocin in micellar formulations was 
studied by quantitatively analyzing the amount of oxytocin recovered from the 
micellar formulations on storage at 40 
o
C for three months. The recovery of 
oxytocin over time at storage temperature of 40 
o
C was influenced by the 
choice of surfactant used in the aqueous solution. The concentration of sucrose 
laurate L1695, Tween 80 and Cremophor RH40 were fixed at 0.1 mg/ml and 
the stability of oxytocin in these solutions were compared with that in control 
which is the citrate buffer with Zn
2+
 divalent metal ions as shown in Figure 
4.10.  After three months, the average oxytocin recovery in the control sample 
is 73.1%. In comparison, average recovery of oxytocin in 0.1 mg/ml each of 
Tween 80 and Cremophor RH40 micellar formulations are lower at 70.7% and 
72.4% respectively (p > 0.05), but is not statistically significant. Conversely, 
for the micellar formulation with 0.1 mg/ml sucrose laurate L1695, average 
oxytocin recovery is 76.5%, demonstrating enhanced thermal stability (p < 






Figure 4.10 Average oxytocin recovery in citrate buffer pH 4.5 with 2 mM 
Zn
2+
 divalent metal ions with 0.1 mg/ml of sucrose laurate L-1695, 
Cremophor RH40 and Tween 80 on storage at 40 
o
C for three months. 
 
In order to discuss the difference in the stabilization or destabilization of 
oxytocin in the various aqueous micellar formulations, it is essential to 
identify the interactions that may be present. Since the surfactants are used at 
concentrations above their CMC values, it is likely that micellization took 
place in the citrate buffer with Zn
2+
 metal ions. Additionally, CMC decreases 
with increased in temperature for nonionic surfactant (Kronberg et al., 2014). 
Therefore at storage temperature of 40 
o
C, micelle structure was preserved.   
In general, these aqueous micellar formulations consists of micelles, salts and 
a peptide (oxytocin).  Since oxytocin is a hydrophilic peptide, it is possible 
that it is localized in the dispersed phase or at the micellar interface as shown 
in Figure 4.11. In the dispersed phase, the stability of oxytocin may be 
influenced by the interaction with salt or metal ions present in the aqueous 
buffer solution. At the interface, the peptide may interact with the polar head 
groups of the surfactants. Additionally, change in properties of the surfactant 

































stability of oxytocin in aqueous formulations. Furthermore, any interactions 
with the micelle is likely to occur at the interface. It is therefore useful to 
analyze the chemical structures of the surfactants and identify the functional 
group that made up the polar interface of the micelles as shown in Figure 4.12. 
For sucrose laurate, the hydrophilic polar head group is made up of sucrose 
functional group while that for Tween 80 consists of polyoxyethylene groups. 
For Cremophor RH40, the polar head group is made up of polyethylene 
glycols and glycerol ethoxylate. 
 
  
Figure 4.11 Illustration of the interactions that are possible in an aqueous 















































where w + x + y + z = 20 
 
Figure 4.12 Chemical structure of (i) sucrose monolaurate (ii) Cremophor 
RH40 and (iii) Tween 80. 
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As discussed previously, micelles of Cremophor RH40 showed negligible 
interaction with the added oxytocin. Hence, oxytocin largely remains in the 
dispersed phase. Complex formation of Zn
2+
 ions with the ether of 
polyoxyethylene group may be hindered by steric interference. Inorganic 
counterions are loosely associated to the micelle and are very mobile 
(Kronberg et al., 2014). With reference to Figure 4.13, it is likely that bulk 
Zn
2+
 ions remain in the dispersed phase with small amount of Zn
2+
 ions 
weakly interacting with the interface of the Cremophor RH40 micelles. 
Oxytocin stabilization by divalent metal ions with citrate buffer is still 
dominant with the presence of Cremophor RH40 micelles. Since a small 
amount of Zn
2+
 interacts with the Cremophor RH40 micelles, it is possible that 
oxytocin stabilization effect by Zn
2+
 ions is reduced. Therefore, the average 
oxytocin recovery is slightly lower in the Cremophor RH40 formulation than 
that in the control citrate buffer with Zn
2+






Figure 4.13 Illustration of the (a) complex formation of Zn
2+
 metal ions 
with oxytocin, and (b) loose association between Cremophor RH40 micelle 
and Zn
2+
 metal ions in a system with Cremophor RH40 micelles, oxytocin and 
Zn
2+
 divalent metal ions. 
 
Oxytocin stability in aqueous formulation was negatively influenced by the 
presence of Tween 80 micelles. In this system, both stabilization and 
destabilization effects may occur. As illustrated in Figure 4.14, first, there 
exists a stabilization effect of oxytocin by the Tween 80 micelle due to 
interaction of oxytocin molecules with the polar head group at the interface of 
the micelles as identified during the thermal stability analysis by DLS. The 
interaction may prevent the degradation of oxytocin due to dimerization and 
aggregation by restricting solvent accessibility. However, the very slight 
increase in the micellar droplet size with the addition of oxytocin may imply 
that oxytocin interaction at the Tween 80 micellar surface is small and that 
most of the oxytocin molecules may still remain in the dispersed phase. In the 





















dispersed phase, some of the Zn
2+
 ions may have formed complex with the 
ether at the polar head group of Tween 80 micelles. This implies that there is a 
competition for interaction with Zn
2+
 ions between the Tween 80 micelles for 
complexation and oxytocin for stabilization. As such, the amount of Zn
2+
 ions 
remaining in the dispersed phase for oxytocin stabilization is substantially 
reduced which resulted in poorer thermal stability. In this system, it seems that 
the destabilization effect may be stronger than the stabilization effect which 











Figure 4.14 Illustration of the (a) complex formation of Zn
2+
 metal ions 
with oxytocin, (b) micellar interaction between Tween 80 micelle and 
oxytocin at the interface, and (c) complex formation between Zn
2+
 metal ions 
and the ether functional group in the polar head group of Tween 80 surfactant, 
in a system with Tween 80 micelles, oxytocin and Zn
2+
 divalent metal ions. 
 
In addition to interactions of oxytocin with the Tween 80 micelles and the 
Zn
2+
 ions, impurities present in Tween 80 surfactant is also likely to affect the 
thermal stability of oxytocin in aqueous phase. It is well known that low level 
of residual peroxide are found in Tween surfactants which may accumulate 





















during long-term storage. This can potentially result in direct degradation of 
pharmaceutical actives or changes to the physico-chemical properties of the 
surfactant (Chou et al., 2005; Ha et al., 2002). Therefore, this may be 
unfavorable to the thermal stability of oxytocin in aqueous formulation as well. 
 
For sucrose laurate formulation, oxytocin may be stabilized in the dispersed 
phased and/or at the interface of the sucrose laurate micelle. As shown in 
Figure 4.15, oxytocin in the aqueous phase is stabilized by the Zn
2+
 ions that 
are present. At the interface, oxytocin exhibits co-surfactant-liked behavior 
and is likely to penetrate into the sucrose laurate monolayer of the micelle. 
This may prevents the oxytocin from contact with the aqueous environment, 
thereby suppressing disulfide exchange reaction due to protonation of the 
disulfide bridge. Furthermore, aggregation of oxytocin molecules can also be 






Figure 4.15 Illustration of the (a) complex formation of Zn
2+
 metal ions 
with oxytocin, (b) micellar interaction between sucrose laurate micelle and 
oxytocin at the interface, where oxytocin exhibits co-surfactant-liked behavior, 
in a system with sucrose laurate micelles, oxytocin and Zn
2+
 divalent metal 
ions. 
 
There have been studies showing that sucrose addition in aqueous formulation 
exhibits stabilizing effect on peptide and protein against aggregation, 
deamidation and oxidation (Kamberi et al., 2005; Ueda et al., 2001). Kamberi 
and coworkers studied mechanism for the stabilization of two peptides, a 
human brain natriuretic peptide [hBNP(1–32)] and a human parathyroid 
hormone [hPTH(1–34)], using sucrose (2001). They conclude in their work 
that the presence of sucrose aid in preserving the native conformation of the 
peptides, thus demonstrating the stabilizing effects. In the sucrose laurate 
micellar formulation with oxytocin, the sucrose functional group of the 
surfactant is exposed to the aqueous environment at the micelle interface. This 
(a) 
(b) 













may also help to keep oxytocin in its native form, thereby providing additional 
stabilization against chemical and physical degradation. 
 
On top of examining the different interactions that may stabilize/destabilize 
oxytocin in aqueous formulations, the temperature effect on the different 
surfactants may influence the average oxytocin recovery as well. Generally, 
nonionic surfactants that contain polyoxyethylene group are affected by 
clouding. When temperature is increased, the polar head group of the 
surfactant shrinks. This leads to weaken interaction between the 
polyoxethylene and water. As such, the surfactant hydration is reduced and 
becomes less water-soluble (Kronberg et al., 2014). Above a specific 
temperature, which is the cloud point, the surfactant becomes insoluble in the 
aqueous phase and a cloudy solution results. Both Cremophor RH40 and 
Tween 80 contain polyoxyethylene functional group and are therefore be 
susceptible to clouding at elevated temperature. However, sucrose ester 
surfactants are unaffected by clouding and are not significantly affected by 
temperature increase (Kunieda et al., 1993; Angeles Pes et al., 1996). This is 
because, comparing with the long polyoxyethylene polar head group, sucrose 
polar head group is more compact and does not undergo large conformational 
changes by hydration (Angeles Pes et al., 1996). In the Cremophor RH40 
formulation, at storage temperature of 40 
o
C, since oxytocin interaction with 
the Cremphor RH40 micelle is minimal, the stability of oxytocin may not be 
substantially affected by cloud point. However, for Tween 80 formulation, 
micelle stabilization effect on oxytocin may be reduced due to the weaken 





may also contribute to the poor thermal stability of oxytocin in aqueous Tween 
80 micellar formulation. 
 
4.4  Effects of surfactant concentration on thermal stability of oxytocin 
in micellar formulation 
 
In this section, emphasis is placed on determining the effect of concentration 
on the thermal stability of oxytocin for Cremophor RH40 and Tween 80. 
Sucrose laurate at 0.1 mg/ml exhibits positive thermal stabilization effect of 
oxytocin in aqueous formulation and is already the maximum non-toxic dose 
for intranasal delivery. Hence, it is interesting to investigate if Cremophor 
RH40 and Tween 80 at higher concentrations would enhance the thermal 
stability. Therefore, thermal stability monitoring was performed at 40 
o
C for 
Cremophor RH40 and Tween 80 at their maximum concentrations, 5 mg/ml 
and 1 mg/ml respectively, which can be safely administered intranasally. The 
results are shown in Figure 4.16. It seems that a higher concentration of 
surfactant does not correspond to better thermal stability of oxytocin in 
aqueous medium. Instead, the destabilization effects are more pronounced 





Figure 4.16 Average oxytocin recovery in citrate buffer pH 4.5 with 2 mM 
Zn
2+
 divalent metal ions with 0.1 mg/ml and 5 mg/ml of Cremophor RH40, 
and 0.1 mg/ml and 1 mg/ml Tween 80 on storage at 40 
o
C for three months. 
 
For Cremophor RH40, higher surfactant concentration resulted in lower 
average oxytocin recovery (p < 0.05). With increased in surfactant 
concentration, the surface area of the micelles increased and creates more 
opportunity for Zn
2+
 to be weakly associated to the micellar interface. As a 
result, the amount of Zn
2+
 ions remaining in the dispersed phase to stabilize 
oxytocin is further reduced.  
 
Conversely, for Tween 80, an increased in surfactant concentration of Tween 
80 did not significantly affect the average oxytocin recovery (p > 0.05). 
Interaction between Zn
2+
 ions is likely more dominant compared with that 
between Zn
2+



































4.5 Effects of addition of mucoadhesives on thermal stability of 
oxytocin in micellar formulation 
 
In order to enhance the bioavailability of oxytocin, mucoadhesives can be 
added into the micellar formulations. It has been shown that sucrose laurate is 
the most suitable surfactant for development of intranasal delivery system for 
oxytocin in aqueous solutions as compared to Cremophor RH40 and Tween 80. 
Therefore, the effect of mucoadhesives addition on the thermal stability of 
oxytocin in aqueous solution will be investigated for the sucrose laurate 
micellar formulation. In this case, carboxymethycellulose sodium was chosen 
as the mucoadhesive use at 2.5 mg/ml which is the maximum tolerable dosage 
for intranasal delivery. The average oxytocin recovered from the formulations 
with mucoadhesives stored at 40 
o
C after three months were quantified as 
displayed in Figure 4.17. 
 
 
Figure 4.17 Average oxytocin recovery in citrate buffer pH 4.5 with 2 mM 
Zn
2+
 divalent metal ions with 2.5 mg/ml carboxylmethylcellulose, with and 
without 0.1 mg/ml of sucrose laurate on storage at 40 
o

































Clearly, the addition of carboxymethylcellulose sodium as mucoadhesives is 
detrimental to the thermal stability of oxytocin in liquid formulation (p < 0.05). 
In a system with only carboxymethylcellulose sodium and oxytocin in the 
citrate buffer with Zn
2+
 metal ions, the average recovery of oxytocin from the 
formulation is only 4.8% after storage at 40 
o
C for three months. If sucrose 
laurate micelles were mixed with carboxymethylcellulose, the average 
oxytocin recovery was increased to 45.8%. Thermal stability of oxytocin was 
enhanced after sucrose laurate addition (p < 0.05).   
 
Carboxylmethylcellulose is an anionic natural polymer. When it is dissolved 
in citrate buffer consisting of Zn
2+
 ions, it may interact with the Zn
2+
 ionically 
as shown in Figure 4.18. Ionic interaction between Zn
2+
 ions and 
carboxymethylcellulose is stronger than complex formation between Zn
2+
 ions 
and oxytocin. As such, oxytocin stabilization effect by the Zn
2+
 ions was 
drastically reduced. In Figure 4.19, the presence of sucrose laurate, some 
oxytocin molecules may be stabilized by the sucrose laurate micelles as 
discussed previously. Therefore, oxytocin recovery was increased. However, 
as compared to the micellar formulation of sucrose laurate without 
carboxymethylcellulose, the thermal stability of oxytocin is significantly 
poorer in the presence of carboxymethylcellulose. The use of 
carboxymethylcellulose as mucoadhesives needs to be reduced such that its 















Figure 4.18 Illustration of the (a) complex formation of Zn
2+
 metal ions 
with oxytocin, and (b) ionic interaction between carboxymethylcellulose and 
Zn
2+
 metal ions at the interface, in a system with carboxymethylcellulose, 
oxytocin and Zn
2+











Figure 4.19 Illustration of the (a) complex formation of Zn
2+
 metal ions 
with oxytocin, (b) ionic interaction between carboxymethylcellulose and Zn
2+
 
metal ions at the interface, and (c) micellar interaction between sucrose laurate 
micelle and oxytocin at the interface, where oxytocin exhibits co-surfactant-
liked behavior, in a system with sucrose laurate micelles, 
carboxymethylcellulose, oxytocin and Zn
2+



































CHAPTER 5 CONCLUSIONS 
 
In this study, micellar formulations with oxytocin were developed. These 
formulations were made up of surfactants and oxytocin in a buffer containing 
a divalent and the potential interactions were studied. First, it was 
demonstrated that the salts present in the formulations are likely water-
structure-making which led to the reduced CMC value for sucrose laurate and 
Cremophor RH40. Zn
2+
 ions in the system may form complex with the ether 
group found in Tween 80 polyoxyethylene chains which resulted in the 
increased in CMC.  
 
Next, it was discovered that oxytocin exhibits co-surfactant-liked behavior 
which caused the reduction in the droplet size in the micellar formulation. 
Cremophor RH40 micellar formulation was not significantly affected by the 
presence of oxytocin. For Tween 80 system, the slight increase in droplet size 
may be due to micellar solubilization of oxytocin by at the surface or shallow 
penetration into the polar head group. 
 
Subsequently, it was found that the co-surfactant-liked behavior of oxytocin in  
the micellar formulations helped to improve its thermal stability by reducing 
the contact with the aqueous environment, thereby suppressing the disulfide 
exchange reaction that destabilize oxytocin in aqueous formulation. 
Additionally, the presence of sucrose functional group at the micellar interface 
may also contributed to the enhanced thermal stability by preserving oxytocin 
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in its native conformation and provide additional stabilization against 
chemical and physical degradation.  
 
In contrast, the thermal stability of oxytocin was slightly poorer in Cremophor 
RH40 formulation due loss of Zn
2+
 ions to stabilize oxytocin in the aqueous 
phase, because some of the Zn
2+
 ions may weakly interact with the Cremophor 
RH40 micelle surface. Tween 80 formulations showed the poorest oxytocin 
thermal stability due to the loss of Zn
2+
 ions in the aqueous phase by complex 
formation at the Tween 80 micelle interface. Hence, the amount of Zn
2+
 ions 
remaining in the aqueous phases for oxytocin stabilization is reduced. 
Furthermore, Tween 80 surfactant is likely to be affected by clouding at 
elevated temperature, leading to poorer stabilization interaction between 
oxytocin and the polar head group on the Tween 80 micellar surface. For 
Cremophor RH40, higher surfactant concentration led to stronger 
destabilization interaction with oxytocin. Hence, the poorer thermal stability 
of oxytocin in aqueous formulations. Finally, it was found that ionic 
interaction between Zn
2+
 ions and carboxymethylcellulose adversely affected 
the thermal stability of oxytocin.  
 
In conclusion, a micellar formulation of oxytocin using 0.1 mg/ml of sucrose 
laurate in 10 mM citrate buffer at pH 4.5 with 2 mM Zn
2+
 divalent metal ions 
was successfully formulated with enhanced thermal stability when compared 





CHAPTER 6 FUTURE WORK 
 
Following success in formulating oxytocin in aqueous medium with enhanced 
thermal stability, further investigation is necessary to incorporate an 
appropriate mucoadhesives to enhance the bioavailability without contributing 
to the degradation of oxytocin. In this study, addition of 
carboxymethycellulose into aqueous formulation showed adverse effect on the 
recovery of oxytocin on storage at 40 
o
C. In order to use 
carboxymethycellulose as mucoadhesives in the micellar formulation, it is 
important to reduce its concentration such that the impact on oxytocin stability 
is controlled at an acceptable level. Besides carboxymethylcellulose, it would 
be desirable to look into other type of mucoadhesives. One particular 
compound of interest is hyaluronan. Even though hyaluronan is deemed a non-
toxic molecule, information on the safe dosage for intranasal delivery was not 
found. It is therefore valuable to evaluate the potential toxicity and safe 
operating concentration on the human nasal cavity before formulation 
development can take place. 
 





 ions in the aqueous micellar formulations since it also show 
stabilization effect of oxytocin in aqueous medium (Avanti et al., 2011). 
  
After formulation development, the efficacy of the formulation may be 
assessed by in vitro monitoring the contractile response of myometrial strips 
obtained from pregnant women following cesarean delivery (Balki et al., 
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2014). The myometrium is the layer of uterine smooth muscle cells in the 
middle of the uterine wall, primarily responsible for the induction of uterine 
contractions. These strips were immersed in Krebs' bicarbonate solution at 37 
o
C pH = 7.4, equilibrated with 5 % carbon dioxide and 95 % oxygen until base 
contraction pattern was established. The contractile response was examined 
based on the effect of dosing the bath with the oxytocin micellar formulation, 
on the contraction pattern.  
 
Furthermore, in vivo animal study may be performed to more accurately 
quantify the efficacy of the micellar formulation. The micellar formulation can 
be intranasally administered at the target delivery site of rats, using a 
micropipette connected to a low density polyethylene tubing (Seju et al., 
2011). Subsequently, a balloon-tipped and water-filled cannula can be placed 
into one uterine horn at the ovarian end to track contractile responses from the 






Afzelius, B. A., 1997. Ciliary dysfunction. in: Crystal, R. G., West, J. B., 
Weibel, E. R., Barnes, P. J. (Eds), The Lung; Scientific Foundations 2
nd
 
edition. Lippincott-Raven, New York. pp 2573–2578. 
Alany, R. G., Rades, T., Agatonovic-Kustrin, S., Davies, N. M., Tucker, I. G., 
2000. Effects of alcohols and diols on the phase behavior of quaternary 
systems. International Journal of Pharmaceutics 196, 141-145. 
Angeles Pes, M., Aramaki, K., Nakamura, N., Kunieda, H., 1996. 
Temperature-insensitive microemulsions in sucrose monoalkanoate system. 
Journal of Colloid and Interface Science 178, 666-672. 
Arakawa, T., Timasheff, S. N., 1982. Stabilization of protein structure by 
sugars. Biochemistry 21, 6536-6544. 
Arechabala, B., Coiffard, C., Rivalland, P., Coiffard, L. J., de Roeck-
Holtzhauer, Y., 1999. Comparison of cytotoxicity of various surfactants tested 
on normal human fibroblast cultures using the neutral red test, MTT assay and 
LDH release. Journal of Applied Toxicology 19, 163-165. 
Arora, P., Sharma, S., Garg, S., 2002. Permeability issues in nasal drug 
delivery. Drug Discovery Today 7, 967-975. 
Avanti, C., Amorij, J., Setyaningsih, D., Hawe, A., Jiskoot, W., Visser, J., 
Kedrov, A., Driessen, A. J. M., Hinrichs, W. L. J., Frijlink, H. W., 2011. A 
new strategy to stabilize oxytocin in aqueous solutions: i. the effects of 
divalent metal ions and citrate buffer. The AAPS Journal 13, 284-311. 
61 
 
Avanti, C., Jiskoot, W., Hinrichs, W. L. J., Frijlink, H. W., 2012a. Current 
strategies for stabilization of therapeutic peptides in aqueous formulations in: 
Avanti, C., Innovative strategies for stabilization of therapeutic peptides in 
aqueous formulations. TIPharma, pp. 15-31. 
Avanti, C., Permentier, H. P., van Dam, A., Poole, R., Jiskoot, W., Frijlink, H. 
W., Hinrichs, W. L. J., 2012b. A new strategy to stabilize oxytocin in aqueous 
solutions: ii. suppression of cysteine-mediated intermolecular reactions by a 
combination of divalent metal ions and citrate. Mol. Pharmaceutics 9, 554-562. 
Back, J. F., Oakenfull, D., Smith, M. B., 1979. Increased thermal stability of 
proteins in the presence of sugars and polyols. American Chemical Society 18, 
5191-5196. 
Baglioni, C., Phipps, R. J., 1990. Nasal absorption of interferon: enhancement 
by surfactant agents. J Interferon Res. 10, 497-504. 
Balki, M., Erik-Soussi, M., Kingdom, J., Carvalho, J. C. A., 2014. 
Comparative efficacy of uterotonic agents: in vitro contractions in isolated 
myometrial strips of laboring and non-labouring women. Canadian Journal of 
Anesthesia 61, 808-818. 
Carale, T. R., Pham, Q. T., Blankschtein, D., 1994. Salt effects on 
intramicellar interactions and micellization of nonionic surfactants in aqueous 
solutions. Langmuir 10, 109-121. 
Chaibva, F. A., Walker, R.B., 2007. Development and validation of a stability-
indicating analytical method for the quantitation of oxytocin in pharmaceutical 
62 
 
dosage forms. Journal of Pharmaceutical and Biomedical Analysis 43, 179-
185. 
Charlton, S., Jones, N. S., Davis, S. S., Illum, L., 2007. Distribution and 
clearance of bioadhesive formulations from the olfactory region in man: effect 
of polymer type and nasal delivery device. European Journal of 
Pharmaceutical Sciences 30, 295-302. 
Chou, D. K., Krishnamurthy, R., Randolph, T. W., Carpenter, J. F., Manning, 
M. C., 2005. Effects of Tween 20 and Tween 80 on the stability of albutropin 
during agitation. Journal of Pharmaceutical Sciences 94, 1368-1381. 
Constantinides, P. P., Scalart, J., 1997. Formulation and physical 
characterization of water-in-oil microemulsions containing long- versus 
medium-chain glycerides. International Journal of Pharmaceutics 158, 57-68. 
Constantino, H. R., Illum, L., Brandt, G., Johnson, P. H., Quay, S. C., 2007. 
Intranasal delivery: physicochemical and therapeutic aspects. International 
Journal of Pharmaceutics 337, 1-24. 
Corbo, D.C., Liu, J. C., Chien, Y. W., 1989. Drug absorption through mucosal 
membranes: effect of mucosal route and penetrant hydrophilicity. 
Pharmaceutical Research 6, 848-852. 
Csóka, G., Marton, S., Zelko, R., Otomo, N., Antal, I., 2007. Application of 
sucrose fatty acid esters in transdermal therapeutic systems. European Journal 
of Pharmaceutics and Biopharmaceutics 65, 233-237. 
63 
 
Dondeti, P., Zia, H., Needham, T. E., 1996. Bioadhesive and formulation 
parameters affecting nasal absorption. International Journal of Pharmaceutics 
127, 115-133. 
Dyer, R. A., Dyk, D., Dresner, A., 2010. The useof uteronic drugs during 
caesarean section. International Journal of Obstetric Anesthesia 19, 313-319. 
El Maghraby, G. M., 2008. Transdermal delivery of hydrocortisone from 
eucalyptus oil microemulsion: effects of cosurfactants. International Journal of 
Pharmaceutics 355, 285-292.  
Ekelund, K., Osth, K., Påhlstorp, C., Björk, E., Ulvenlund, S., Johansson, F., 
2005. Correlation between epithelial toxicity and surfactant structure as 
derived from the effects of polyethyleneoxide surfactants on caco-2 cell 
monolayers and pig nasal mucosa. Journal of Pharmaceutical Sciences 94, 
730-744. 
Fosgerau, K., Hoffmann, T., 2015. Peptide therapeutics: current status and 
future directions. Drug Discovery Today 20, 122-128. 
Graff, C. L., Pollack, G. M., 2005. Functional evidence for p-glycoprotein at 
the nose-brain barrier. Pharmaceutical Research 22, 86-93. 
Groot, A. N. J. A.; Vree, T. B.; Hogerzeil, H. V.; Walker, G. J. A., 1994. 
Stability of oral oxytocics in tropical climates: results of simulation studies on 
oral ergometrine, oral methylergometrine, buccal oxytocin and buccal 
desamino-oxytocin. World Health Organization, Geneva. 
Ha, E., Wang, W., Wang, J., 2002. Peroxide formation in polysorbate 80 and 
protein stability. Journal of Pharmaceutical Sciences 91, 2252-2264. 
64 
 
Hawe, A., Poole, R., Romeijn, S., Kasper, P., van der Heijden, R., Jiskoot, W., 
2009. Towards heat-stable oxytocin formulations: analysis of degradation 
kinetics and identification of degradation products. Pharmaceutical Research 
26, 1679-1688.  
Hersey, S. J., Jackson, R. T., 1987. Effect of bile salts on nasal permeability in 
vitro. J Pharm Sci. 76, 876-879. 
Hirai, S., Yashiki T., Matsuzawa, T., Mima, H., 1981. Absorption of drugs 
from the nasal mucosa of rat. International Journal of Pharmaceutics 7, 317-
325. 
Illum, L., Farraj, N. F., Davis, S. S., 1994. Chitosan as a novel nasal delivery 
system for peptide drugs. Pharmaceutical Research 11, 1186-1189. 
Illum, L., 2003. Nasal drug delivery: possibilities, problems and solutions. 
Journal of Controlled Release 87, 187-198. 
Kamberi, M., Kim, Y. J., Jun, B., Riley, C. M., 2005. The effects of sucrose on 
stability of human brain natriuretic peptide [hBNP (1-32)] and human 
parathyroid hormone [hPTH (1-34)]. J. Pept. Res. 66, 348-356. 
Kandimalla, K. K., Donovan, M. D., 2005. Transport of hydroxyzine and 
triprolidine across bovine olfactory mucosa: role of passive diffusion in the 
direct nose-to-brain uptake of small molecules. International Journal of 
Pharmaceutics 302, 133-144. 
Karasulu, E., Yavasoğlu, A., Evrensanal, Z., Uyanikgil, Y., Karasulu, HY., 
2008. Permeation studies and histological examination of sheep nasal mucosa 
65 
 
following administration of different nasal formulations with or without 
absorption enhancers. Drug Delivery 15, 219-225. 
Kaspar, A. A., Reichert, J. M., 2013. Future directions for peptide therapeutics 
development. Drug Discovery Today 18, 807-817. 
Kerwin, B. A., 2007. Polysorbates 20 and 80 used in the formulation of 
protein biotherapeutics: structure and degradation pathways. Journal of 
Pharmaceutical Sciences 97, 2924-2935. 
Kim, D., 2008. In vitro cellular models for nasal drug absorption studies in: 
Ehrhardt, C., Kim, K. (Eds), Drug absorption studies: in situ, in vitro and in 
silico models. Springer, USA. pp. 216-234. 
Kimbell, J. S., Gross, E. A., Richardson, R. B., Conolly, R. B., Morgan, K. T., 
1997. Correlation of regional formaldehyde flux predictions with the 
distribution of formaldehyde-induced squamous metaplasia in F344 rat nasal 
passages. Mutation Research/Fundamental and Molecular Mechanisms of 
Mutagenesis 380, 143-154. 
Kozlov, M. M., Helfrich, W., 1992. Effects of cosurfactant on the stretching 
and bending elasticities of a surfactant monolayer. Langmuir 8, 2792-2797. 
Kronberg, B., Holmberg, K., Lindman, B., 2014. Surfactant Self-Assembly: 
Beyond the Spherical Micelle, in: Surface Chemistry of Surfactants and 
Polymers. John Wiley & Sons, Ltd. pp. 113-136. 
Kunieda, H., Ushio, N., Nakano, A., Miura, M., 1993. Three-phase behavior in 
mixed sucrose alkanoate and polyethyleneglycol alkyl ether system. Journal of 
Colloid and Interface Science 159, 37-44. 
66 
 
Kürti, L., Veszelka, S., Bocsik, A., Dung, N. T., Ozsvári, B., Puskás, L. G., 
Kittel, A., Szabó-Révész, P., Deli, M. A., 2012. The effect of sucrose esters on 
a culture model of the nasal barrier. Toxicology in Vitro 26, 445-454. 
Lee, J. C., Timasheff, S. N., 1981. The stabilization of proteins by sucrose. 
Journal of Biological Chemistry 256, 7193-7201. 
Lethem, M. I., 1993. The role of tracheobronchial mucus in drug 
administration to the airways. Advanced Drug Delivery Reviews 11, 271-298. 
Ludwig, M., Tobin, V. A., Callahan, M. F., Papadaki, E., Becker, A., 
Engelmann, M., Leng, G., 2013. Intranasal application of vasopressin fails to 
elicit changes in brain immediate early gene expression, neural activity and 
behavioral performance of rats. J. Neuroendocrinol. 25, 655-667. 
MacDonald, C., Lyzenga, W., Shao, D., Agu, R. U., 2010. Water-soluble 
organic solubilizers for in vitro drug delivery studies with respiratory 
epithelial cells: Selection based on various toxicity indicators. Drug Delivery 
17, 434-442. 
Marttin, E., Schipper, N. G. M., Verhoef, J. C., Merkus, F. W. H. M., 1998. 
Nasal mucociliary clearance as a factor in nasal drug delivery. Advanced Drug 
Delivery Reviews 29, 18-38. 
Matsaridou, I., Barmpalexis, P., Salis, A., Nikolakakis, I., 2012. The influence 
of surfactant HLB and oil/surfactant ratio on the formation and properties of 
self-emulsifying pellets and microemulsion reconstitution. AAPS 
PharmSciTech 13, 1319-1330. 
67 
 
Mishima, M., Wakita, Y., Nakano, M., 1987. Studies on the promoting effects 
of medium chain fatty acids salts on nasal absorption of insulin in rats. Journal 
of Pharmacobio-dynamics 10, 624-631. 
 Mygind, N., Dahl, R., 1998. Anatomy, physiology and function of the nasal 
cavities in health and disease. Advanced Drug Delivery Reviews 29, 3-12. 
Nachtmann, F., Krummen, K., Maxl, F., Riemer, E., 1981. Oxytocin. 
Analytical Profiles of Drug Substances 10, 563-596. 
Nishikido, M., Matuura, R., 1977. The effect of added inorganic salts on the 
micelle formation of nonionic surfactants in aqueous solutions. Bulletin of the 
Chemical Society of Japan 50, 1690-1694. 
Park, S. H., Song, C. H., Pak, S. C., Flouret, G., Laird, W. J., 2000. The effect 
of oxytocin antagonist on uterus response to exogenous oxytocin. Journal of 
Korean Medical Science 15, 299-302. 
Pires, A., Fortuna, A., Alves, G., Falcão, A., 2009. Intranasal drug delivery: 
how, why and what for? J. Pharm. Pharmaceut. Sci. 12, 288-211. 
Probst, R., Grevers, G., 2011. Basic otorhinolaryngology: a step-by-step 
learning guide. Thieme, New York. 
Prankerd, R. J., Nguyen, T., Ibrahim, J. P., Bischof, R. J., Nassta, G. C., 
Olerile, L. D., Russell, A. S., Meiser, F., Parkington, H. C., Coleman, H. A., 
Morton, D. A. V., McIntosh, M. P., 2013. Pulmonary delivery of ultra-fine 
oxytocin dry powder formulation: potential for treatment of postpartum 
haemorrhage in developing countries. PLoS ONE 8(12). 
68 
 
Ray, A., Némethy, G., 1971. Effects of ionic protein denaturants on micelle 
formation by nonionic detergents. Journal of American Chemical Society 93, 
6787-6793. 
Royston, E., Armstrong, S., 1989. Preventing maternal deaths. World Health 
Organization, Geneva. 
Ruiz, C. C., 2008. Chapter 3 Effect of Temperature and Salt Addition, in: 
Sugar-Based Surfactants: Fundamentals and Applications. CRC Press. pp. 61-
104 
Say, L., Chou, D., Gemmill, A., Tunçalp, Ö., Moller, A., Daniels, J., 
Gülmezoglu, A. M., Temmerman, M., Alkema, L., 2014. Global causes of 
maternal death: a WHO systematic analysis. The Lancet Global Health 2, 
e323-e333. 
Seju, U., Kumar, A., Sawant, K. K., 2011. Development and evaluation of 
olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and 
in vivo studies. Acta Biomaterialia 7, 4169-4176. 
Schott, H., 1973. Salting in of nonionic surfactants by complexation with 
inorganic salts. Journal of Colloid and Interface Science 43, 150-155. 
Schott, H., Han, S. K., 1976. Effect of inorganic additives on solutions of 
nonionic surfactants iii: CMC’s and surface properties. Journal of 
Pharmaceutical Sciences 65, 975-978. 
Tadros, T. F., 2005. Surfactants in Pharmaceutical Formulations, in: Applied 




Ueda, T.,Nagata, M., Imoto, T., 2001. Aggregation and chemical reaction in 
hen lysozyme caused by heating at pH 6 are depressed by osmolytes, sucrose 
and trehalose. J. Biochem 130, 491-496. 
Ugwoke, M. I., Agu, R. U., Vanbilloen, H., Baetens, J., Augustijns, P., 
Verbeke, N., Mortelmans, L., Verbruggen, A., Kinget, R., Bormans, G., 2000a. 
Scintigraphic evaluation in rabbits of nasal drug delivery systems based on 
carbopol 971p® and carboxymethylcellulose. Journal of Controlled Release 
68, 207-214. 
Ugwoke, M. I., Agu, R. U., Jorissen, M., Augustijns, P., Sciot, R., Verbeke, N., 
Kinget, R., 2000b. Nasal toxicological investigations of Carbopol 971P 
formulation of apomorphine: effects on ciliary beat frequency of human nasal 
primary cell culture and in vivo on rabbit nasal mucosa. European Journal of 
Pharmaceutical Sciences 9, 387-396. 
Ugwoke, M. I., Agu, R. U., Jorissen, M., Augustijns, P., Sciot, R., Verbeke, N., 
Kinget, R., 2000c. Toxicological investigations of the effects 
carboxylmethylcellulose on ciliary beat frequency of human nasal epithelial 
cells in primary suspension culture and in vivo on rabbit nasal mucosa. 
International Journal of Pharmaceutics 205, 43-51. 
Ugwoke, M. I., Agu, R. U., Verbeke, N., Kinget, R., 2005. Nasal 
mucoadhesive drug delivery: background, applications, trends and future 
perspectives. Advanced Drug Delivery Reviews 57, 1640-1665. 
United Nations. Millennium Development Goals and Beyond 2015. Retrieved, 
1
st
 July 2015, from http://www.un.org/millenniumgoals/maternal.shtml. 
70 
 
Van Dogen, P. W. J., van Roosmalen, J., de Boer, C. N., van Rooy, J., 1991. 
Oxytocics for the prevention of postpartum haemorrhages. A review. 
Pharmaceutisch Weekblad Scientific edition 13, 238-243 
Verdugo, P., 1990. Goblet cells secretion and mucogenesis. Annual Review of 
Physiology 52, 157-176. 
Walter, R., Schwartz, I. L., Darnell, J. H., Urry, D. W., 1971. Relation of the 
conformation of oxytocin to the biology of neurohypophyseal hormones. Pro. 
Nat. Acad. Sci. USA 68, 1355-1359. 
Wang, J., Tabata, Y., Morimoto, K., 2006. Aminated gelatin microspheres as a 
nasal delivery system for peptide drugs: evaluation of in vitro release and in 
vivo insulin absorption in rats. Journal of Controlled Release 113, 31-37. 
Washington, N., Steele, R. J. C., Jackson, S. J., Bush, D., Mason, J., Gill, D. 
A., Pitt, K., Rawlins, D. A., 2000. Determination of baseline human nasal pH 
and the effect of intranasally administered buffers. International Journal of 
Pharmaceutics 198, 139-146. 
Westin, U., Piras, E., Jansson, B., Bergström, U., Dahlin, M., Brittebo, E., 
Björk, E., 2005. Transfer of morphine along the olfactory pathway to the 
central nervous system after nasal administration to rodents. European Journal 
of Pharmaceutical Sciences 24, 565-573. 
WHO,  2014. Trends in maternal mortality: 1990 to 2013 Estimates by WHO, 




Youan, B. C., Hussain, A., Nguyen, N. T., 2003. Evaluation of sucrose esters 
as alternative surfactants in microencapsulation of proteins by the solvent 
evaporation method. AAPS, PharmSci 5, 1-9. 
Zaki, N. M., Mortadaa, N. D., Awada, G. A. S., Abd ElHadyb, S. S., 2006. 
Rapid-onset intranasal delivery of metoclopramide hydrochloride: part ii: 
safety of various absorption enhancers and pharmacokinetic evaluation. 





Hydrodynamic droplet size distribution 
 
The hydrodynamic droplet size distributions measured by Dynamic Light 
Scattering using Malvern Zetasizer Nano ZS (Malvern Instrument Ltd., UK) 
between 20 – 60 oC are shown in in Figures I.1 – I.6. As shown in Figures 
4.5 and 4.7, formulations with sucrose laurate L-1695 and Tween 80 micelles 
have polydispersity indices greater than 0.2, implying the presence of bimodal 
or broad size distribution. The droplet size distributions for micellar 
formulations with 0.1 mg/ml sucrose laurate, with and without 0.1 mg/ml 
oxytocin, are shown in Figures I.1 and I.2 respectively. Figures I.3 and I.4 
show the droplet size distributions for micellar formulations with 0.1 mg/ml 






Figure I.1 Hydrodynamic droplet size against intensity for 0.1 mg/ml sucrose 
laurate micellar formulation, without oxytocin. Data combined for all 






Figure I.2 Hydrodynamic droplet size against intensity for 0.1 mg/ml sucrose 
laurate micellar formulation, with 0.1 mg/ml oxytocin. Data combined for all 






Figure I.3 Hydrodynamic droplet size against intensity for 0.1 mg/ml Tween 
80 micellar formulation, without oxytocin. Data combined for all temperature 






Figure I.4 Hydrodynamic droplet size against intensity for 0.1 mg/ml Tween 
80 micellar formulation, with 0.1 mg/ml oxytocin. Data combined for all 






As shown in Figure 4.6, formulations with Cremophor RH40 micelles have 
polydispersity indices less than 0.2, implying a monodisperse sample. The 
droplet size distributions for micellar formulations with 0.1 mg/ml Cremophor 




Figure I.5 Hydrodynamic droplet size against intensity for 0.1 mg/ml 
Cremophor RH40 micellar formulation, without oxytocin. Data combined for 






Figure I.6 Hydrodynamic droplet size against intensity for 0.1 mg/ml 
Cremophor RH40 micellar formulation, with 0.1 mg/ml oxytocin. Data 
combined for all temperature points between 20 and 60 
o
C. 
